The Role of Methylation of Host and/or Human Papillomavirus (HPV) DNA in Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Lesions

• Published in: International journal of molecular sciences Vol. 24; no. 7; p. 6479
• Main Authors: Dovnik, Andraž, Poljak, Mario
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30.03.2023; MDPI
• Subjects: Cellular biology; Cervical cancer; DNA; DNA Methylation; Female; Human papillomavirus; Human Papillomavirus Viruses; Humans; Meta-analysis; Papillomaviridae - genetics; Papillomavirus Infections - complications; Papillomavirus Infections - genetics; Papillomavirus Infections - pathology; Pregnancy; Pregnancy complications; Review; Systematic review; Uterine Cervical Dysplasia - pathology; Uterine Cervical Neoplasms - genetics; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - therapy; Womens health; United States > US; cervical intraepithelial lesion; human papillomavirus; gene methylation
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24076479

Cervical intraepithelial neoplasia grade 2 (CIN2) is an intermediate stage between CIN 1, which is a low-grade lesion, and CIN3, which is the immediate precursor of cervical cancer (CC). Traditionally, CIN2 was regarded as a high-grade lesion and was treated with conization or ablative methods. In recent years, there has been a shift in the management of younger patients, who are now more often being managed conservatively due to frequent spontaneous CIN2 regression and possible adverse effects of treatment on future pregnancies. Because the risk of progression to CC still exists with conservative management, a personalized approach is needed to identify patients with a higher probability of progression. In this regard, research has focused on the role of host and human papillomavirus (HPV) gene methylation. This systematic review summarizes the current knowledge regarding conservative CIN2 management focusing on the main methylation markers and its implementation in conservative CIN2 management, and it describes major ongoing longitudinal studies on the subject. The review showed that DNA methylation is an accurate predictor of disease progression and a valid triage tool for HPV-positive women, with CIN2 performing better than triage cytology. Because virtually all CCs are methylation-positive, methylation-negative women at baseline have an extremely low risk of CC.